ADR,SEQ,PT,HLT,HLGT,SOC_ABBREV,FATAL_YN
1,1,Ecchymosis,Purpura and related conditions,Skin vascular abnormalities,Skin,N
1,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
1,3,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
1,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
2,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
2,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
3,1,Injection site inflammation,Injection site reactions,Administration site reactions,Genrl,N
4,1,Gynaecomastia,Breast disorders NEC,Breast disorders,Repro,N
5,1,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,Y
6,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
7,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
7,2,Colitis ulcerative,Colitis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
7,3,Diarrhoea haemorrhagic,Diarrhoea (excl infective),Gastrointestinal motility and defaecation conditions,Gastr,N
8,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
8,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
8,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
9,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
10,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
10,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
11,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
11,2,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
12,1,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
13,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
14,1,Chest discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
14,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
15,1,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
16,1,Arthritis bacterial,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
16,2,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
16,3,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
16,4,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
16,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
16,6,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
16,7,Wound infection staphylococcal,Staphylococcal infections,Bacterial infectious disorders,Infec,N
17,1,Gastroenteritis bacillus,Bacillary infections,Bacterial infectious disorders,Infec,N
18,1,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
18,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
18,3,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
19,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
20,1,Angina pectoris,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
21,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
21,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
22,1,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
22,2,Erythema,Erythemas,Epidermal and dermal conditions,Skin,N
22,3,Headache,Headaches NEC,Headaches,Nerv,N
22,4,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
23,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
24,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
25,1,Ovarian cancer,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,N
26,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
26,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
26,3,Splenomegaly,Spleen disorders,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
26,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
27,1,Infected skin ulcer,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
28,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
28,2,Soft tissue infection,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,N
28,3,Staphylococcal infection,Staphylococcal infections,Bacterial infectious disorders,Infec,N
28,4,Subcutaneous abscess,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
29,1,Blood pressure increased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
29,2,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
29,3,Mouth ulceration,Stomatitis and ulceration,Oral soft tissue conditions,Gastr,N
29,4,Oropharyngeal pain,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
30,1,Acute myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
30,2,Diabetes mellitus,Diabetes mellitus (incl subtypes),Glucose metabolism disorders (incl diabetes mellitus),Metab,N
30,3,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
30,4,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
31,1,Chest pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
31,2,Cholelithiasis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
31,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
32,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
33,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
33,2,Cardiac failure congestive,Heart failures NEC,Heart failures,Card,N
33,3,Hypertensive nephropathy,Renal hypertension and related conditions,Renal disorders (excl nephropathies),Renal,N
33,4,Infected skin ulcer,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
33,5,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,Y
33,6,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
33,7,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
33,8,Urinary tract infection,Urinary tract infections,Infections - pathogen unspecified,Infec,N
34,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
35,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
36,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
37,1,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,N
37,2,Renal failure,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
37,3,Streptococcal sepsis,Streptococcal infections,Bacterial infectious disorders,Infec,Y
38,1,Interstitial lung disease,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,Y
39,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
39,2,Ovarian cancer metastatic,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,Y
39,3,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
40,1,Aphasia,Cortical dysfunction NEC,Neurological disorders NEC,Nerv,N
40,2,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
40,3,Ischaemic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
41,1,Bowen's disease,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
42,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
43,1,Varicella,Herpes viral infections,Viral infectious disorders,Infec,N
44,1,Autoantibody test,Autoimmunity analyses,Immunology and allergy investigations,Inv,N
44,2,Blood creatinine increased,Renal function analyses,Renal and urinary tract investigations and urinalyses,Inv,N
44,3,Goodpasture's syndrome,Glomerulonephritis and nephrotic syndrome,Nephropathies,Renal,N
45,1,Metastases to pleura,Metastases to specified sites,Metastases,Neopl,N
45,2,Ovarian cancer metastatic,Ovarian neoplasms malignant (excl germ cell),Reproductive neoplasms female malignant and unspecified,Neopl,Y
46,1,Chronic obstructive pulmonary disease,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
46,2,Pneumonia pseudomonal,Pseudomonal infections,Bacterial infectious disorders,Infec,Y
47,1,Infected skin ulcer,Skin structures and soft tissue infections,Infections - pathogen unspecified,Infec,N
48,1,Blood lactate dehydrogenase increased,Tissue enzyme analyses NEC,Enzyme investigations NEC,Inv,N
48,2,Haemoglobin decreased,Red blood cell analyses,Haematology investigations (incl blood groups),Inv,N
48,3,Haemolysis,Haemolyses NEC,Haemolyses and related conditions,Blood,N
49,1,Neoplasm malignant,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
49,2,Oesophageal carcinoma,Oesophageal neoplasms malignant,Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
49,3,Rheumatoid arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
50,1,Bronchospasm,Bronchospasm and obstruction,Bronchial disorders (excl neoplasms),Resp,N
51,1,Squamous cell carcinoma,Neoplasms malignant site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
52,1,C-reactive protein decreased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
52,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
52,3,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
52,4,White blood cell count decreased,White blood cell analyses,Haematology investigations (incl blood groups),Inv,N
53,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
53,2,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
53,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
54,1,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
54,2,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
54,3,Inflammation,Inflammations,General system disorders NEC,Genrl,N
54,4,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
54,5,Respiratory disorder,Respiratory tract disorders NEC,Respiratory disorders NEC,Resp,N
55,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
56,1,Myocarditis,Noninfectious myocarditis,Myocardial disorders,Card,N
57,1,Cerebrovascular accident,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
57,2,Hypersensitivity vasculitis,Skin vasculitides,Skin vascular abnormalities,Skin,N
57,3,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
58,1,Lung neoplasm malignant,Respiratory tract and pleural neoplasms malignant cell type unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
59,1,Basal cell carcinoma,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
60,1,Peripheral ischaemia,"Peripheral vasoconstriction, necrosis and vascular insufficiency","Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
60,2,Peripheral vascular disorder,Peripheral vascular disorders NEC,Vascular disorders NEC,Vasc,N
60,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
61,1,Renal cancer,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
61,2,Renal cell carcinoma recurrent,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
62,1,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
62,2,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
62,3,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
62,4,Pulmonary oedema,Pulmonary oedemas,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
63,1,Malignant melanoma,Skin melanomas (excl ocular),Skin neoplasms malignant and unspecified,Neopl,N
64,1,Gastrointestinal carcinoma,Gastrointestinal neoplasms malignant NEC,Gastrointestinal neoplasms malignant and unspecified,Neopl,N
65,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
66,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
67,1,Bronchiolitis,Viral infections NEC,Viral infectious disorders,Infec,N
67,2,Nodule,Mass conditions NEC,Tissue disorders NEC,Genrl,N
68,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
68,2,Gastroenteritis,Abdominal and gastrointestinal infections,Infections - pathogen unspecified,Infec,N
69,1,Pneumonia adenoviral,Adenoviral infections,Viral infectious disorders,Infec,N
69,2,Varicella zoster pneumonia,Herpes viral infections,Viral infectious disorders,Infec,N
70,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
71,1,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
71,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
71,3,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
71,4,Hypotension,Vascular hypotensive disorders,Decreased and nonspecific blood pressure disorders and shock,Vasc,N
71,5,Lip swelling,Oral soft tissue swelling and oedema,Oral soft tissue conditions,Gastr,N
71,6,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
71,7,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
71,8,Urticaria,Urticarias,Angioedema and urticaria,Skin,N
72,1,Cachexia,General nutritional disorders NEC,Appetite and general nutritional disorders,Metab,N
72,2,Death,Death and sudden death,Fatal outcomes,Genrl,N
72,3,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
72,4,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
72,5,Dysphagia,Gastrointestinal signs and symptoms NEC,Gastrointestinal signs and symptoms,Gastr,N
72,6,Metastases to liver,Metastases to specified sites,Metastases,Neopl,Y
72,7,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
72,8,Myocardial ischaemia,Ischaemic coronary artery disorders,Coronary artery disorders,Card,N
72,9,Therapeutic product ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
72,10,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
73,1,Maxillofacial sinus neoplasm,Respiratory tract and pleural neoplasms malignancy unspecified NEC,Respiratory and mediastinal neoplasms malignant and unspecified,Neopl,N
73,2,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
74,1,Renal cancer,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,N
74,2,Renal cell carcinoma recurrent,Renal neoplasms malignant,Renal and urinary tract neoplasms malignant and unspecified,Neopl,Y
75,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
76,1,Device related infection,Infections NEC,Infections - pathogen unspecified,Infec,N
77,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
78,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
79,1,Cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
80,1,Abdominal pain,Gastrointestinal and abdominal pains (excl oral and throat),Gastrointestinal signs and symptoms,Gastr,N
80,2,Ascites,Peritoneal and retroperitoneal disorders,Peritoneal and retroperitoneal conditions,Gastr,N
81,1,Accidental exposure to product,Accidental exposures to product,Medication errors and other product use errors and issues,Inj&P,N
81,2,Stillbirth,Stillbirth and foetal death,Abortions and stillbirth,Preg,N
82,1,Cholecystitis,Cholecystitis and cholelithiasis,Gallbladder disorders,Hepat,N
82,2,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
83,1,Pancreatitis,Acute and chronic pancreatitis,Exocrine pancreas conditions,Gastr,N
84,1,Hair colour changes,Pilar disorders NEC,Skin appendage conditions,Skin,N
85,1,Skin cancer,Skin neoplasms malignant and unspecified (excl melanoma),Skin neoplasms malignant and unspecified,Neopl,N
86,1,Injection site erythema,Injection site reactions,Administration site reactions,Genrl,N
86,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
86,3,Injection site pruritus,Injection site reactions,Administration site reactions,Genrl,N
86,4,Injection site swelling,Injection site reactions,Administration site reactions,Genrl,N
86,5,Injection site warmth,Injection site reactions,Administration site reactions,Genrl,N
87,1,Injection site rash,Injection site reactions,Administration site reactions,Genrl,N
87,2,Injection site vesicles,Injection site reactions,Administration site reactions,Genrl,N
88,1,Face oedema,Oedema NEC,General system disorders NEC,Genrl,N
88,2,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
89,1,Dermatitis bullous,Bullous conditions,Epidermal and dermal conditions,Skin,N
89,2,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
90,1,Meningitis viral,Viral infections NEC,Viral infectious disorders,Infec,N
91,1,Abortion spontaneous,Abortions spontaneous,Abortions and stillbirth,Preg,N
91,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
92,1,Intestinal ischaemia,Gastrointestinal vascular occlusion and infarction,Gastrointestinal vascular conditions,Gastr,Y
93,1,Fall,Non-site specific injuries NEC,Injuries NEC,Inj&P,N
93,2,Rib fracture,Thoracic cage fractures and dislocations,Bone and joint injuries,Inj&P,N
94,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
94,2,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
95,1,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
95,2,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
96,1,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
96,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
96,3,Lethargy,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
96,4,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
97,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
97,2,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
97,3,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
97,4,Unevaluable event,General signs and symptoms NEC,General system disorders NEC,Genrl,N
98,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
98,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
98,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
98,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
98,5,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
98,6,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
98,7,Immobile,Disability issues,Lifestyle issues,SocCi,N
98,8,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
98,9,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
98,10,Juvenile idiopathic arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
98,11,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
98,12,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
98,13,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
98,14,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
98,15,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
98,16,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
98,17,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
98,18,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
98,19,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
98,20,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
98,21,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
99,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
100,1,Amniotic fluid volume decreased,Foetal and neonatal diagnostic procedures,Foetal and neonatal investigations,Inv,N
100,2,Arthritis,Arthropathies NEC,Joint disorders,Musc,N
101,1,Atelectasis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
101,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
101,3,Obstruction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
101,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
102,1,Atelectasis,Parenchymal lung disorders NEC,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
102,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
103,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
103,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
104,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
104,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
105,1,Bone marrow disorder,Haematological disorders,Haematological disorders NEC,Blood,N
106,1,Chills,Feelings and sensations NEC,General system disorders NEC,Genrl,N
106,2,Confusional state,Confusion and disorientation,Deliria (incl confusion),Psych,N
106,3,Dizziness,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
106,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
106,5,Headache,Headaches NEC,Headaches,Nerv,N
106,6,Product quality issue,Product quality issues NEC,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
107,1,Polycythaemia,Polycythaemia (excl rubra vera),Red blood cell disorders,Blood,N
108,1,Impaired healing,Healing abnormal NEC,Tissue disorders NEC,Genrl,N
108,2,Rhinitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
108,3,Rhinorrhoea,Upper respiratory tract signs and symptoms,Respiratory tract signs and symptoms,Resp,N
109,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
110,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
111,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
111,2,Talipes,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
112,1,Arthropathy,Arthropathies NEC,Joint disorders,Musc,N
112,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
112,3,Gout,Disorders of purine metabolism,Purine and pyrimidine metabolism disorders,Metab,N
112,4,Headache,Headaches NEC,Headaches,Nerv,N
112,5,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
112,6,Muscular weakness,Muscle weakness conditions,Muscle disorders,Musc,N
112,7,Psoriatic arthropathy,Psoriatic arthropathies,Joint disorders,Musc,N
113,1,Breast cancer,Breast and nipple neoplasms malignant,Breast neoplasms malignant and unspecified (incl nipple),Neopl,N
114,1,Aspergilloma,Aspergillus infections,Fungal infectious disorders,Infec,N
114,2,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
115,1,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
115,2,Gastrointestinal viral infection,Viral infections NEC,Viral infectious disorders,Infec,N
116,1,Aortic valve stenosis,Aortic valvular disorders,Cardiac valve disorders,Card,N
116,2,Cardiac failure,Heart failures NEC,Heart failures,Card,Y
117,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
117,2,Cryopyrin associated periodic syndrome,Musculoskeletal and connective tissue disorders of limbs congenital,Musculoskeletal and connective tissue disorders congenital,Cong,N
117,3,Meningitis aseptic,Central nervous system and spinal infections,Infections - pathogen unspecified,Infec,N
117,4,Therapeutic response decreased,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
118,1,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
118,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
118,3,Respiratory symptom,Respiratory signs and symptoms NEC,Respiratory tract signs and symptoms,Resp,N
119,1,Influenza,Influenza viral infections,Viral infectious disorders,Infec,N
119,2,Myocardial infarction,Ischaemic coronary artery disorders,Coronary artery disorders,Card,Y
119,3,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
120,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,Y
120,2,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
120,3,Bacterial sepsis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
120,4,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
120,5,Epstein-Barr virus infection,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
120,6,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
121,1,Amyloidosis,Amyloidoses,Immune disorders NEC,Immun,N
121,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
121,3,Renal impairment,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
122,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,Y
122,2,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
122,3,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
122,4,Device related sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
122,5,Epstein-Barr virus infection,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
122,6,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
123,1,Local reaction,General signs and symptoms NEC,General system disorders NEC,Genrl,N
124,1,Cervical dysplasia,Cervix disorders NEC,Cervix disorders (excl infections and inflammations),Repro,N
124,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
124,3,Papilloma viral infection,Papilloma viral infections,Viral infectious disorders,Infec,N
124,4,Smear site unspecified abnormal,Histopathology procedures NEC,"Investigations, imaging and histopathology procedures NEC",Inv,N
125,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
126,1,Congenital megacolon,Intestinal disorders congenital,Gastrointestinal tract disorders congenital,Cong,N
127,1,Blood pressure decreased,Vascular tests NEC (incl blood pressure),Cardiac and vascular investigations (excl enzyme tests),Inv,N
127,2,Body temperature increased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
127,3,Cardiac arrest,Ventricular arrhythmias and cardiac arrest,Cardiac arrhythmias,Card,Y
127,4,Hyperventilation,Breathing abnormalities,Respiratory disorders NEC,Resp,N
127,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
128,1,Haemorrhagic stroke,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,N
128,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
129,1,Pancreatic carcinoma metastatic,Pancreatic neoplasms malignant (excl islet cell and carcinoid),Gastrointestinal neoplasms malignant and unspecified,Neopl,Y
130,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,N
130,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
130,3,Overdose,Overdoses NEC,Overdoses and underdoses NEC,Inj&P,N
131,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
131,2,International normalised ratio increased,Coagulation and bleeding analyses,Haematology investigations (incl blood groups),Inv,N
131,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
131,4,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
131,5,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
132,1,Multiple sclerosis,Multiple sclerosis acute and progressive,Demyelinating disorders,Nerv,N
133,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
133,2,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
133,3,Galactorrhoea,Lactation disorders,Breast disorders,Repro,N
133,4,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
133,5,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
133,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
133,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
133,8,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
134,1,HIV infection,Retroviral infections,Viral infectious disorders,Infec,N
135,1,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
136,1,Liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
137,1,Allergic hepatitis,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
137,2,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
138,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
138,2,Atypical mycobacterial infection,Atypical mycobacterial infections,Mycobacterial infectious disorders,Infec,N
138,3,Cytomegalovirus infection reactivation,Cytomegaloviral infections,Viral infectious disorders,Infec,N
138,4,Cytomegalovirus viraemia,Cytomegaloviral infections,Viral infectious disorders,Infec,N
138,5,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
138,6,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
138,7,Pancytopenia,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
138,8,Pneumonitis,Lower respiratory tract inflammatory and immunologic conditions,Lower respiratory tract disorders (excl obstruction and infection),Resp,N
138,9,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
139,1,Cytomegalovirus viraemia,Cytomegaloviral infections,Viral infectious disorders,Infec,N
139,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
139,3,Epstein-Barr viraemia,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
139,4,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
139,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
139,6,Pleural effusion,Pneumothorax and pleural effusions NEC,Pleural disorders,Resp,N
139,7,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
140,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
140,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
140,3,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
140,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
140,5,Ejection fraction decreased,Cardiac function diagnostic procedures,Cardiac and vascular investigations (excl enzyme tests),Inv,N
140,6,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
140,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
140,8,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
140,9,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
140,10,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
140,11,Still's disease,Rheumatoid arthropathies,Joint disorders,Musc,N
141,1,BK virus infection,Polyomavirus infections,Viral infectious disorders,Infec,N
141,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
141,3,Encephalitis viral,Viral infections NEC,Viral infectious disorders,Infec,N
141,4,Epstein-Barr viraemia,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
141,5,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
141,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
141,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
141,8,Viraemia,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
142,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
142,2,Guillain-Barre syndrome,Acute polyneuropathies,Peripheral neuropathies,Nerv,N
142,3,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
142,4,Human herpesvirus 6 infection,Herpes viral infections,Viral infectious disorders,Infec,N
142,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
142,6,Varicella zoster virus infection,Herpes viral infections,Viral infectious disorders,Infec,N
143,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
143,2,BK virus infection,Polyomavirus infections,Viral infectious disorders,Infec,N
143,3,Cytomegalovirus infection,Cytomegaloviral infections,Viral infectious disorders,Infec,N
143,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
143,5,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
143,6,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
143,7,Viral haemorrhagic cystitis,Viral infections NEC,Viral infectious disorders,Infec,N
144,1,Acute graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
144,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
144,3,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
144,4,Serum amyloid A protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
145,1,Acute graft versus host disease in intestine,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
145,2,Acute graft versus host disease in skin,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
145,3,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
145,4,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
145,5,Fasciitis,Musculoskeletal and connective tissue infections and inflammations NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
145,6,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
145,7,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
145,8,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
145,9,Osteonecrosis,Bone disorders NEC,Bone disorders (excl congenital and fractures),Musc,N
146,1,Plasma cell myeloma,Plasma cell myelomas,Plasma cell neoplasms,Neopl,N
147,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
147,2,Growth failure,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
147,3,Human herpesvirus 6 infection,Herpes viral infections,Viral infectious disorders,Infec,N
147,4,Hyperthyroidism,Thyroid hyperfunction disorders,Thyroid gland disorders,Endo,N
147,5,Impaired quality of life,Social issues NEC,Lifestyle issues,SocCi,N
147,6,Serum amyloid A protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
147,7,Therapy non-responder,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
148,1,Aspergillus infection,Aspergillus infections,Fungal infectious disorders,Infec,N
148,2,Bacterial infection,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
148,3,Clonus,Neurological signs and symptoms NEC,Neurological disorders NEC,Nerv,N
148,4,Pupillary light reflex tests abnormal,Ophthalmic function diagnostic procedures,"Neurological, special senses and psychiatric investigations",Inv,N
149,1,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
149,2,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
150,1,Foetal anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
150,2,Foetal monitoring abnormal,Foetal and neonatal diagnostic procedures,Foetal and neonatal investigations,Inv,N
150,3,Hydrops foetalis,Foetal complications NEC,Foetal complications,Preg,N
150,4,Small for dates baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
151,1,Hypoaesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
151,2,Paraesthesia,Paraesthesias and dysaesthesias,Neurological disorders NEC,Nerv,N
152,1,Prostate cancer,Prostatic neoplasms malignant,Reproductive neoplasms male malignant and unspecified,Neopl,N
153,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
154,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
154,2,Osteomyelitis,Bone and joint infections,Infections - pathogen unspecified,Infec,N
155,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
156,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
156,2,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,Y
156,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
157,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
157,2,Foetal growth restriction,Foetal growth complications,Foetal complications,Preg,N
158,1,C-reactive protein increased,Protein analyses NEC,Protein and chemistry analyses NEC,Inv,N
158,2,Decreased appetite,Appetite disorders,Appetite and general nutritional disorders,Metab,N
158,3,Drug reaction with eosinophilia and systemic symptoms,Dermatitis ascribed to specific agent,Epidermal and dermal conditions,Skin,N
158,4,Eosinophilia,Eosinophilic disorders,White blood cell disorders,Blood,N
158,5,Lymphadenopathy,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
158,6,Oedema peripheral,Oedema NEC,General system disorders NEC,Genrl,N
158,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
158,8,Periorbital swelling,Ocular disorders NEC,Eye disorders NEC,Eye,N
158,9,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
158,10,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
158,11,Rash pruritic,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
158,12,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
158,13,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
159,1,Encephalitis viral,Viral infections NEC,Viral infectious disorders,Infec,N
159,2,Epstein-Barr viraemia,Epstein-Barr viral infections,Viral infectious disorders,Infec,N
159,3,Growth retardation,Musculoskeletal and connective tissue conditions NEC,Musculoskeletal and connective tissue disorders NEC,Musc,N
159,4,Herpes zoster,Herpes viral infections,Viral infectious disorders,Infec,N
159,5,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
159,6,Rash papular,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
159,7,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,Y
159,8,Viraemia,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
160,1,Adenovirus infection,Adenoviral infections,Viral infectious disorders,Infec,N
160,2,Cardiac failure,Heart failures NEC,Heart failures,Card,N
160,3,Left ventricular dysfunction,Myocardial disorders NEC,Myocardial disorders,Card,N
160,4,Pericardial effusion,Pericardial disorders NEC,Pericardial disorders,Card,N
160,5,Pseudomonas infection,Pseudomonal infections,Bacterial infectious disorders,Infec,N
161,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
161,2,Familial mediterranean fever,Immune system abnormalities congenital,Immune system disorders congenital,Cong,N
161,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
161,4,Product storage error,Product storage errors and issues in the product use system,Medication errors and other product use errors and issues,Inj&P,N
162,1,Immune thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
162,2,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
163,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,Y
164,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
164,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
165,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
165,2,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
165,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
166,1,Encephalopathy,Encephalopathies NEC,Encephalopathies,Nerv,N
166,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
166,3,Status epilepticus,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
167,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
167,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
168,1,Multiple-drug resistance,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
168,2,Status epilepticus,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
169,1,General physical health deterioration,General signs and symptoms NEC,General system disorders NEC,Genrl,N
169,2,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
169,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
170,1,Cerebral haemorrhage,Central nervous system haemorrhages and cerebrovascular accidents,Central nervous system vascular disorders,Nerv,Y
170,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
171,1,Brain stem syndrome,Nervous system disorders NEC,Neurological disorders NEC,Nerv,N
171,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
171,3,Superior sagittal sinus thrombosis,Cerebrovascular venous and sinus thrombosis,Central nervous system vascular disorders,Nerv,Y
172,1,Gestational diabetes,Pregnancy complicated by maternal disorders,Maternal complications of pregnancy,Preg,N
172,2,Lower respiratory tract infection,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
172,3,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
173,1,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
173,2,Hypertransaminasaemia,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
174,1,Enterococcal bacteraemia,Enterococcal infections,Bacterial infectious disorders,Infec,N
174,2,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
174,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
175,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
175,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
175,3,Pneumonia pneumococcal,Streptococcal infections,Bacterial infectious disorders,Infec,N
175,4,Serum ferritin decreased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
176,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
176,2,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
176,3,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
176,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
176,5,Pulmonary embolism,Pulmonary thrombotic and embolic conditions,Pulmonary vascular disorders,Resp,N
176,6,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
176,7,Thrombocytopenia,Thrombocytopenias,Platelet disorders,Blood,N
177,1,Atypical pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,Y
177,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
178,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
178,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
179,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
179,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
180,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
180,2,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
181,1,Fluid imbalance,Electrolyte imbalance NEC,Electrolyte and fluid balance conditions,Metab,N
181,2,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
181,3,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
181,4,Transplant failure,Transplantation complications,Procedural related injuries and complications NEC,Inj&P,N
182,1,Alanine aminotransferase increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
183,1,Fungal sepsis,Fungal infections NEC,Fungal infectious disorders,Infec,Y
183,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
184,1,Injection site bruising,Injection site reactions,Administration site reactions,Genrl,N
185,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
185,2,Hepatic function abnormal,Hepatic enzymes and function abnormalities,Hepatic and hepatobiliary disorders,Hepat,N
185,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
186,1,Hepatic enzyme increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
186,2,Jaundice,Cholestasis and jaundice,Hepatic and hepatobiliary disorders,Hepat,N
186,3,Nausea,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
187,1,Headache,Headaches NEC,Headaches,Nerv,N
187,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
188,1,Costochondritis,Cartilage disorders,"Tendon, ligament and cartilage disorders",Musc,N
188,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
189,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
189,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
190,1,Drug-induced liver injury,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
190,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
191,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
191,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
192,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
193,1,Hepatotoxicity,Hepatocellular damage and hepatitis NEC,Hepatic and hepatobiliary disorders,Hepat,N
193,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
194,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
195,2,Respiratory depression,Breathing abnormalities,Respiratory disorders NEC,Resp,N
196,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
197,1,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
197,2,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
198,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
198,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
199,1,Alopecia,Alopecias,Skin appendage conditions,Skin,N
199,2,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
199,3,Necrosis ischaemic,Non-site specific necrosis and vascular insufficiency NEC,"Arteriosclerosis, stenosis, vascular insufficiency and necrosis",Vasc,N
199,4,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
200,1,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
201,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
202,1,Bone marrow failure,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
202,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
202,3,Seizure,Seizures and seizure disorders NEC,Seizures (incl subtypes),Nerv,N
203,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
203,2,Periorbital cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
203,3,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
204,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
204,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
205,1,Multiple organ dysfunction syndrome,General signs and symptoms NEC,General system disorders NEC,Genrl,Y
205,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
206,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
206,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
207,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
207,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
208,1,Death,Death and sudden death,Fatal outcomes,Genrl,Y
208,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
209,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
210,1,Contusion,Skin injuries NEC,Injuries NEC,Inj&P,N
210,2,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
210,3,Rash erythematous,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
210,4,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
211,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
212,1,Haemorrhage,Haemorrhages NEC,Vascular haemorrhagic disorders,Vasc,N
212,2,Lymphadenopathy mediastinal,Lymphatic system disorders NEC,"Spleen, lymphatic and reticuloendothelial system disorders",Blood,N
212,3,Neutropenia,Neutropenias,White blood cell disorders,Blood,N
212,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
212,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
212,6,Thrombosis,Non-site specific embolism and thrombosis,Embolism and thrombosis,Vasc,N
213,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
213,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
214,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
214,2,Skin tightness,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
215,1,Incorrect route of product administration,Product administration errors and issues,Medication errors and other product use errors and issues,Inj&P,N
215,2,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
216,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
216,2,Cytokine release syndrome,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
216,3,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
216,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
216,5,Immune effector cell-associated neurotoxicity syndrome,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
216,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
216,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
216,8,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
216,9,Product use issue,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
216,10,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
217,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
217,2,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
218,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
218,2,Cytokine release syndrome,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
218,3,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
218,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
218,5,Immune effector cell-associated neurotoxicity syndrome,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
218,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
218,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
218,8,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
218,9,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
219,1,Atrial fibrillation,Supraventricular arrhythmias,Cardiac arrhythmias,Card,N
219,2,Myopathy,Myopathies,Muscle disorders,Musc,N
219,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
220,1,Chromaturia,Urinary abnormalities,Urinary tract signs and symptoms,Renal,N
220,2,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
220,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
220,4,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
220,5,Tachycardia,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
221,1,Liver function test abnormal,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
221,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
221,3,Pneumocystis jirovecii pneumonia,Pneumocystis infections,Fungal infectious disorders,Infec,N
222,1,Illness,General signs and symptoms NEC,General system disorders NEC,Genrl,N
223,1,Catastrophic reaction,Stress disorders,Anxiety disorders and symptoms,Psych,N
223,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
223,3,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,Y
223,4,Oesophageal rupture,Oesophageal ulcers and perforation,Gastrointestinal ulceration and perforation,Gastr,N
224,1,Anaemia,Anaemias NEC,Anaemias nonhaemolytic and marrow depression,Blood,N
224,2,Deafness neurosensory,Hearing losses,Hearing disorders,Ear,N
224,3,Myelosuppression,Marrow depression and hypoplastic anaemias,Anaemias nonhaemolytic and marrow depression,Blood,N
225,1,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,Y
225,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
226,1,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
226,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
227,1,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
227,2,Periorbital cellulitis,Bacterial infections NEC,Bacterial infectious disorders,Infec,N
227,3,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
228,1,Arthralgia,Joint related signs and symptoms,Joint disorders,Musc,N
228,2,Cough,Coughing and associated symptoms,Respiratory disorders NEC,Resp,N
228,3,Dyspnoea,Breathing abnormalities,Respiratory disorders NEC,Resp,N
228,4,Fatigue,Asthenic conditions,General system disorders NEC,Genrl,N
228,5,Hyperglycaemia,Hyperglycaemic conditions NEC,Glucose metabolism disorders (incl diabetes mellitus),Metab,N
228,6,Immobile,Disability issues,Lifestyle issues,SocCi,N
228,7,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
228,8,Joint swelling,Joint related signs and symptoms,Joint disorders,Musc,N
228,9,Juvenile idiopathic arthritis,Rheumatoid arthropathies,Joint disorders,Musc,N
228,10,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
228,11,Pain,Pain and discomfort NEC,General system disorders NEC,Genrl,N
228,12,Pruritus,Pruritus NEC,Epidermal and dermal conditions,Skin,N
228,13,Pyrexia,Febrile disorders,Body temperature conditions,Genrl,N
228,14,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
228,15,Somnolence,Disturbances in consciousness NEC,Neurological disorders NEC,Nerv,N
228,16,Swelling,General signs and symptoms NEC,General system disorders NEC,Genrl,N
228,17,Tonsillitis,Upper respiratory tract infections,Infections - pathogen unspecified,Infec,N
228,18,Weight decreased,Physical examination procedures and organ system status,Physical examination and organ system status topics,Inv,N
229,1,Injection site pain,Injection site reactions,Administration site reactions,Genrl,N
230,1,Acute kidney injury,Renal failure and impairment,Renal disorders (excl nephropathies),Renal,N
230,2,Cytomegalovirus viraemia,Cytomegaloviral infections,Viral infectious disorders,Infec,N
230,3,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
231,1,Product use in unapproved indication,"Medication errors, product use errors and issues NEC",Medication errors and other product use errors and issues,Inj&P,N
231,2,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
232,1,Faeces pale,Faecal abnormalities NEC,Gastrointestinal signs and symptoms,Gastr,N
232,2,Gastritis,Gastritis (excl infective),Gastrointestinal inflammatory conditions,Gastr,N
232,3,Liver function test increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
232,4,Transaminases increased,Hepatobiliary function diagnostic procedures,Hepatobiliary investigations,Inv,N
233,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
233,2,Cytokine release syndrome,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
233,3,Diffuse large B-cell lymphoma,Diffuse large B-cell lymphomas,Lymphomas non-Hodgkin's B-cell,Neopl,Y
233,4,Disease progression,General signs and symptoms NEC,General system disorders NEC,Genrl,N
233,5,Immune effector cell-associated neurotoxicity syndrome,Encephalopathies toxic and metabolic,Encephalopathies,Nerv,N
233,6,Neoplasm progression,Neoplasms unspecified malignancy and site unspecified NEC,Miscellaneous and site unspecified neoplasms malignant and unspecified,Neopl,N
233,7,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
233,8,Toxicity to various agents,Poisoning and toxicity,"Exposures, chemical injuries and poisoning",Inj&P,N
234,1,Discomfort,Pain and discomfort NEC,General system disorders NEC,Genrl,N
234,2,Skin reaction,Dermal and epidermal conditions NEC,Epidermal and dermal conditions,Skin,N
235,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
235,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
235,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
236,1,Dehydration,Total fluid volume decreased,Electrolyte and fluid balance conditions,Metab,N
236,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
236,3,Vomiting,Nausea and vomiting symptoms,Gastrointestinal signs and symptoms,Gastr,N
237,1,Bronchopulmonary aspergillosis,Aspergillus infections,Fungal infectious disorders,Infec,N
238,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
238,2,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
238,3,Haemophagocytic lymphohistiocytosis,Immune and associated conditions NEC,Immune disorders NEC,Immun,N
238,4,Hypertension,Vascular hypertensive disorders NEC,Vascular hypertensive disorders,Vasc,N
238,5,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
238,6,Septic shock,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
239,1,Malaise,Asthenic conditions,General system disorders NEC,Genrl,N
240,1,Sepsis,"Sepsis, bacteraemia, viraemia and fungaemia NEC",Infections - pathogen unspecified,Infec,N
241,1,Adverse drug reaction,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
242,1,Bradycardia foetal,Rate and rhythm disorders NEC,Cardiac arrhythmias,Card,N
242,2,Foetal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
242,3,Premature baby,Gestational age and weight conditions,Neonatal and perinatal conditions,Preg,N
243,1,Intentional product misuse,Intentional product misuses,Off label uses and intentional product misuses/use issues,Inj&P,N
243,2,Pneumonia,Lower respiratory tract and lung infections,Infections - pathogen unspecified,Infec,N
244,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
244,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
245,1,Drug ineffective,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
245,2,Maternal exposure during pregnancy,"Exposures associated with pregnancy, delivery and lactation","Exposures, chemical injuries and poisoning",Inj&P,N
245,3,Normal newborn,Normal newborn status,"Pregnancy, labour, delivery and postpartum conditions",Preg,N
246,1,Treatment failure,Therapeutic and nontherapeutic responses,Therapeutic and nontherapeutic effects (excl toxicity),Genrl,N
247,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
247,2,Lipid proteinosis,Inborn errors of lipid metabolism,Metabolic and nutritional disorders congenital,Cong,N
247,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
248,1,Injection site reaction,Injection site reactions,Administration site reactions,Genrl,N
248,2,Secondary amyloidosis,Amyloidoses,Immune disorders NEC,Immun,N
249,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
250,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
250,2,Cutaneous amyloidosis,Skin and subcutaneous conditions NEC,Skin and subcutaneous tissue disorders NEC,Skin,N
250,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
250,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
250,5,Still's disease,Rheumatoid arthropathies,Joint disorders,Musc,N
251,1,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
251,2,Intentional dose omission,Intentional product use issues,Off label uses and intentional product misuses/use issues,Inj&P,N
251,3,Product supply issue,Product supply and availability issues,"Product quality, supply, distribution, manufacturing and quality system issues",Prod,N
252,1,Enterococcal bacteraemia,Enterococcal infections,Bacterial infectious disorders,Infec,N
252,2,Human herpesvirus 6 infection reactivation,Herpes viral infections,Viral infectious disorders,Infec,N
252,3,Infection,Infections NEC,Infections - pathogen unspecified,Infec,N
252,4,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
252,5,Pseudomonal bacteraemia,Pseudomonal infections,Bacterial infectious disorders,Infec,Y
253,1,Necrotising fasciitis,Muscle and soft tissue infections,Infections - pathogen unspecified,Infec,Y
253,2,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
254,1,Condition aggravated,General signs and symptoms NEC,General system disorders NEC,Genrl,N
254,2,Hypersensitivity,Allergic conditions NEC,Allergic conditions,Immun,N
254,3,Off label use,Off label uses,Off label uses and intentional product misuses/use issues,Inj&P,N
254,4,Rash,"Rashes, eruptions and exanthems NEC",Epidermal and dermal conditions,Skin,N
254,5,Serum ferritin increased,Mineral and electrolyte analyses,"Water, electrolyte and mineral investigations",Inv,N
254,6,Still's disease,Rheumatoid arthropathies,Joint disorders,Musc,N
